Novel Therapeutics for the Treatment of Alzheimer's and Parkinson's Disease
- PMID: 31914906
- DOI: 10.2174/1381612826666200107161051
Novel Therapeutics for the Treatment of Alzheimer's and Parkinson's Disease
Abstract
Neurodegenerative diseases are a leading apprehension in underdeveloped and developed countries. The advancement of medical science is synonymous with an increase in life expectancy, which results in an aging population. Neurodegenerative diseases in the older population are on the rise globally. This review sums up the novel therapeutic approaches for Alzheimer's and Parkinson's disease. Although most neurodegenerative diseases occur due to the accumulation of misfolded proteins, the mechanisms are not completely understood. Currently, only prophylactic therapies are available and none are preventive in nature. The World Health Organisation estimates that neurodegenerative diseases that cause cognitive and motor impairments will be the second most ubiquitous cause of death in the next decade, hence the need for novel therapeutic targets for these diseases is demanded. In Alzheimer's, β-amyloid and tau proteinopathies are prevalent, whereas a prion-like increase of α- synuclein is the characteristic trait of Parkinson's disease.
Keywords: Alzheimer’s; Neurodegenerative disease; Parkinson’s; novel therapeutics; prophylactic; proteinopathies..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
The prion-like propagation hypothesis in Alzheimer's and Parkinson's disease.Curr Opin Neurol. 2019 Apr;32(2):266-271. doi: 10.1097/WCO.0000000000000672. Curr Opin Neurol. 2019. PMID: 30724769 Review.
-
Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.J Neurochem. 2016 Oct;139(2):162-180. doi: 10.1111/jnc.13772. Epub 2016 Sep 15. J Neurochem. 2016. PMID: 27529376 Review.
-
Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases.Cold Spring Harb Perspect Biol. 2016 Nov 1;8(11):a023630. doi: 10.1101/cshperspect.a023630. Cold Spring Harb Perspect Biol. 2016. PMID: 27580631 Free PMC article. Review.
-
Could it be that neurodegenerative diseases are infectious?Rev Neurol (Paris). 2019 Sep-Oct;175(7-8):427-430. doi: 10.1016/j.neurol.2019.07.003. Epub 2019 Jul 26. Rev Neurol (Paris). 2019. PMID: 31358351 Review.
-
Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Neurotherapeutics. 2016 Jan;13(1):179-89. doi: 10.1007/s13311-015-0397-z. Neurotherapeutics. 2016. PMID: 26494242 Free PMC article. Review.
Cited by
-
Investigating Bacopa monnieri L. Therapeutic Potential for the Treatment of Neurological Diseases.Curr Pharm Des. 2024;30(13):1016-1030. doi: 10.2174/0113816128288698240305094945. Curr Pharm Des. 2024. PMID: 38500283 Review.
-
Phytochemicals Targeting BDNF Signaling for Treating Neurological Disorders.Brain Sci. 2025 Feb 27;15(3):252. doi: 10.3390/brainsci15030252. Brain Sci. 2025. PMID: 40149774 Free PMC article. Review.
-
Neuronal Glial Crosstalk: Specific and Shared Mechanisms in Alzheimer's Disease.Brain Sci. 2022 Jan 3;12(1):75. doi: 10.3390/brainsci12010075. Brain Sci. 2022. PMID: 35053818 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical